Literature DB >> 9058165

Hepatocellular carcinoma.

R C Johnson.   

Abstract

Hepatocellular carcinoma is a deadly disease and the most common form of primary liver disease in the world. A great deal of new research into all aspects of the disease is reported each year. This review examined many of the most recent publications concerning HCC and reports some of the more interesting developments. The paper attempts to highlight information which may be of practical use to health care providers and provides a source of references for further investigation. Some of the latest information concerning prognosis, etiology, diagnostic techniques is summarized. This article also discusses advances in the therapy, both medical and surgical, for Hepatocellular carcinoma.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9058165

Source DB:  PubMed          Journal:  Hepatogastroenterology        ISSN: 0172-6390


  4 in total

Review 1.  Hepatocellular carcinoma.

Authors:  S Badvie
Journal:  Postgrad Med J       Date:  2000-01       Impact factor: 2.401

2.  In vivo assessment of angioarchitecture and microcirculation in experimental liver cancer: a new model in rats.

Authors:  S M Maksan; H Paulo; E Ryschich; C Kuntz; M M Gebhard; E Klar; J Schmidt
Journal:  Dig Dis Sci       Date:  2003-02       Impact factor: 3.199

3.  1,2-dioleoyl-3-trimethylammonium-propane (DOTAP)-formulated, immune-stimulatory vascular endothelial growth factor a small interfering RNA (siRNA) increases antitumoral efficacy in murine orthotopic hepatocellular carcinoma with liver fibrosis.

Authors:  Miroslaw Kornek; Veronika Lukacs-Kornek; Andreas Limmer; Esther Raskopf; Ursula Becker; Maren Klöckner; Tilman Sauerbruch; Volker Schmitz
Journal:  Mol Med       Date:  2008 Jul-Aug       Impact factor: 6.354

4.  Identification and characterization of a novel human hepatocellular carcinoma-associated gene.

Authors:  Z X Wang; H Y Wang; M C Wu
Journal:  Br J Cancer       Date:  2001-10-19       Impact factor: 7.640

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.